Trial reportGenome medicine2026
A short-term randomized clinical trial testing feasibility of and physiological responses to a Ruminococcus torques strain in healthy overweight humans.
Trial report in Genome medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05448274 (An Intervention Study to Explore Potential Metabolic Effects of Ruminococcus Torques Strain ATCC 27756 in Healthy Adults), which is not on this map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
An Intervention Study to Explore Potential Metabolic Effects of Ruminococcus Torques Strain ATCC 27756 in Healthy Adults
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe human gut microbiota interacts with host biology as exemplified by the effects of the Ruminococcus torques (RT) ATCC 27756 strain-a commensal human intestinal bacterial strain that synthesizes the polypeptides RORDEP1 and RORDEP2 which in rodents improve metabolism. Motivated by the metabolic effects of the RT strain in the rodent host, we explored in a short-term double blind and placebo-controlled randomized cross-over trial the feasibility and potential physiological responses of the same bacterial strain in humans.
methodsThe trial undertaken at Herlev and Gentofte Hospital, Denmark included 32 healthy overweight adults. Decided by block randomization with blocks of six, we infused either 3.1 × 10
resultsThe infusion of the bacterium was safe and well-tolerated. We found no effects on the primary endpoint of the trial. Compared to placebo, short-term RT infusion induced a relative rise in plasma concentrations of glucagon-like-peptide-1 (GLP-1) and peptide YY (PYY) in parallel with a relative decline in gastric inhibitory polypeptide (GIP). These intestinal hormone responses mirrored those previously reported from studies in rats. The abundance of secondary bile acids in plasma as well as a plasma marker of bone remodeling increased after infusion of RT compared to placebo. Measures of glucose tolerance, energy expenditure, cutaneous thermography, and main markers of systemic low-grade inflammation remained unchanged.
conclusionsDuodenal infusion during six hours of the RT ATCC 27756 strain in healthy overweight humans shows that the bacterial strain is well tolerated, and the short-term effects on intestinal hormone release align with those previously reported in rodents.
trial registrationThe trial is registered prospectively in ClinicalTrials.gov on 2022-06-28 with ID NCT05448274 ( https://clinicaltrials.gov/study/NCT05448274?intr=ruminococcus%20torques&viewType=Card&rank=1 ).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.